Relevant bibliographies by topics / Chemotherapeutic and Targeted Therapies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Chemotherapeutic and Targeted Therapies'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chemotherapeutic and Targeted Therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Chemotherapeutic and Targeted Therapies"

1

Khunger, Niti, Shankila Mittal, and SatyaPal Kataria. "Nail changes with chemotherapeutic agents and targeted therapies." Indian Dermatology Online Journal 13, no. 1 (2022): 13. http://dx.doi.org/10.4103/idoj.idoj_801_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Reyes-Habito, Claire Marie, and Ellen K. Roh. "Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer." Journal of the American Academy of Dermatology 71, no. 2 (2014): 203.e1–203.e12. http://dx.doi.org/10.1016/j.jaad.2014.04.014.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Norden, Andrew D., Jan Drappatz, and Patrick Y. Wen. "Targeted drug therapy for meningiomas." Neurosurgical Focus 23, no. 4 (2007): E12. http://dx.doi.org/10.3171/foc-07/10/e12.

Full text
Abstract:
✓ Although advances in surgery, radiation therapy, and stereotactic radiosurgery have significantly improved the treatment of meningiomas, there remains an important subset of patients whose tumors are refractory to conventional therapy. Treatment with traditional chemotherapeutic agents has provided minimal benefit. In this review, the role of targeted molecular therapies for recurrent or progressive meningiomas is discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

Chung, Clement, and Rosetta Lee. "Neoadjuvant Chemotherapeutic and Targeted Therapies for Early-stage, High-risk Breast Cancer." European Oncology & Haematology 10, no. 01 (2014): 28. http://dx.doi.org/10.17925/eoh.2014.10.1.28.

Full text
Abstract:
Neoadjuvant or preoperative chemotherapy is the preferred treatment for locally advanced, inflammatory and early-stage high-risk breast cancers. Patients with locally advanced breast cancers are candidates for neoadjuvant therapy because their tumours are often not amenable to resection. On the other hand, patients are candidates for neoadjuvant chemotherapy if the breast-conserving surgery is not possible. At present, anthracycline- and taxane-based chemotherapy regimens remain as the cornerstone for neoadjuvant therapy in early breast cancer, but there is a clear need for effective therapies
APA, Harvard, Vancouver, ISO, and other styles
5

Setlai, Botle Precious, Rodney Hull, Meshack Bida, et al. "Immunosuppressive Signaling Pathways as Targeted Cancer Therapies." Biomedicines 10, no. 3 (2022): 682. http://dx.doi.org/10.3390/biomedicines10030682.

Full text
Abstract:
Immune response has been shown to play an important role in defining patient prognosis and response to cancer treatment. Tumor-induced immunosuppression encouraged the recent development of new chemotherapeutic agents that assists in the augmentation of immune responses. Molecular mechanisms that tumors use to evade immunosurveillance are attributed to their ability to alter antigen processing/presentation pathways and the tumor microenvironment. Cancer cells take advantage of normal molecular and immunoregulatory machinery to survive and thrive. Cancer cells constantly adjust their genetic ma
APA, Harvard, Vancouver, ISO, and other styles
6

Lee, Eun Hye, Se Hyun Kwak, Chi Young Kim, Hye Ran Gwon, Eun Young Kim, and Yoon Soo Chang. "New targeted therapies for non-small cell lung cancer." Journal of the Korean Medical Association 66, no. 3 (2023): 180–90. http://dx.doi.org/10.5124/jkma.2023.66.3.180.

Full text
Abstract:
Background: Lung cancer is representative of a high frequency and high mortality disease and ranks at the top in incidence and mortality in Korea, when excluding thyroid cancer. In this manuscript, we focused on current targeted therapies for lung cancer used widely in the medical field.Current Concepts: The majority of patients with lung cancer cannot be treated with surgery only and require chemotherapeutics or radiation therapy. Currently, classical chemotherapeutic agents, targeted agents, and immune checkpoint inhibitors are the most widely used. Recently, the Research and Development of
APA, Harvard, Vancouver, ISO, and other styles
7

Taylor, Wesley F., Maria Yanez, Sara E. Moghadam, et al. "7-epi-Clusianone, a Multi-Targeting Natural Product with Potential Chemotherapeutic, Immune-Modulating, and Anti-Angiogenic Properties." Molecules 24, no. 23 (2019): 4415. http://dx.doi.org/10.3390/molecules24234415.

Full text
Abstract:
Targeted therapies have changed the treatment of cancer, giving new hope to many patients in recent years. The shortcomings of targeted therapies including acquired resistance, limited susceptible patients, high cost, and high toxicities, have led to the necessity of combining these therapies with other targeted or chemotherapeutic treatments. Natural products are uniquely capable of synergizing with targeted and non-targeted anticancer regimens due to their ability to affect multiple cellular pathways simultaneously. Compounds which provide an additive effect to the often combined immune ther
APA, Harvard, Vancouver, ISO, and other styles
8

Nerkar, A. G. "Metastatic melanomas: Treatment overview." Current Trends in Pharmacy and Pharmaceutical Chemistry 3, no. 4 (2021): 50–55. http://dx.doi.org/10.18231/j.ctppc.2021.013.

Full text
Abstract:
Melanomas especially metastatic melanoma chemotherapeutic treatment has been discussed in the review article. The recent advancement in the chemotherapy being Immunotherapy targeted therapy, combination therapy, targeted therapy, combination therapies and biochemotherpies all of which have been discussed in this review article.
APA, Harvard, Vancouver, ISO, and other styles
9

Qian, Xian-ling, Jun Li, Ran Wei, Hui Lin, and Li-xia Xiong. "Internal and External Triggering Mechanism of “Smart” Nanoparticle-Based DDSs in Targeted Tumor Therapy." Current Pharmaceutical Design 24, no. 15 (2018): 1639–51. http://dx.doi.org/10.2174/1381612824666180510094607.

Full text
Abstract:
Background: Anticancer chemotherapeutics have a lot of problems via conventional Drug Delivery Systems (DDSs), including non-specificity, burst release, severe side-effects, and damage to normal cells. Owing to its potential to circumventing these problems, nanotechnology has gained increasing attention in targeted tumor therapy. Chemotherapeutic drugs or genes encapsulated in nanoparticles could be used to target therapies to the tumor site in three ways: “passive”, “active”, and “smart” targeting. Objective: To summarize the mechanisms of various internal and external “smart” stimulating fac
APA, Harvard, Vancouver, ISO, and other styles
10

Starace, Michela, Luca Rapparini, and Stephano Cedirian. "Skin Malignancies Due to Anti-Cancer Therapies." Cancers 16, no. 11 (2024): 1960. http://dx.doi.org/10.3390/cancers16111960.

Full text
Abstract:
Skin cancers involve a significant concern in cancer therapy due to their association with various treatment modalities. This comprehensive review explores the increased risk of skin cancers linked to different anti-cancer treatments, including classic immunosuppressants such as methotrexate (MTX), chemotherapeutic agents such as fludarabine and hydroxyurea (HU), targeted therapies like ibrutinib and Janus Kinase inhibitors (JAKi), mitogen-activated protein kinase pathway (MAPKP) inhibitors, sonic hedgehog pathway (SHHP) inhibitors, and radiotherapy. MTX, a widely used immunosuppressant in dif
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Chemotherapeutic and Targeted Therapies"

1

Tucker, Catherine Amanda. "Targeted therapies in mantle cell lymphoma." Thesis, University of British Columbia, 2008. http://hdl.handle.net/2429/922.

Full text
Abstract:
Mantle cell lymphoma (MCL) is characterized by the presence of the t(11 ;14)(g13 ;g32) translocation which results in cyclin Dl over-expression. MCL is one of the most difficult lymphoproliferative disorders to manage with a median survival rate of 43 months from diagnosis. The poor prognosis associated with MCL is due in large part to its late classification as a separate clinical entity leading to a dearth in available pre-clinical models. The specific objectives of the research described in this thesis were (1) to establish MCL preclinical models of disease and (2) to evaluate deregulated c
APA, Harvard, Vancouver, ISO, and other styles
2

Yau, Chung-cheung, and 邱宗祥. "Molecular targeted therapies in advanced hepatocellular carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2012. http://hub.hku.hk/bib/B48421145.

Full text
Abstract:
With the recent advances in the knowledge of hepato-carcinogenesis, there has been encouraging development in the molecular targeted therapy for patients with advanced hepatocellular carcinoma (HCC). Sorafenib, an anti-angiogenic multi-targeted receptor tyrosine kinase inhibitor, has become the standard of treatment in HCC patients with Child-Pugh A cirrhosis. Nevertheless, the benefits and safety profile of sorafenib in the majority of the unselected advanced HCC patients and other patient subgroups are still unclear. More importantly, the survival benefit associated with sorafenib use is ge
APA, Harvard, Vancouver, ISO, and other styles
3

Zaman, Noreen Tasneem. "Targeted and stimuli-responsive polymers as chemotherapeutic delivery systems." Thesis, Massachusetts Institute of Technology, 2008. http://hdl.handle.net/1721.1/43217.

Full text
Abstract:
Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Chemical Engineering, 2008.<br>Includes bibliographical references.<br>Successful administration of chemotherapeutic agents for cancer treatment requires a balance between the efficacy and the safety of the drug. This often limits physicians to a very narrow therapeutic window. To avoid the harmful side-effects, chemotherapeutic agents may be administered at a suboptimal dose. This is not only a less effective treatment, but can lead to the development of drug resistance by cancerous cells. The therapeutic window can be increased
APA, Harvard, Vancouver, ISO, and other styles
4

Guerreiro-Lucas, Luciano Andre. "Longitudinal intravital evaluation of tumour vasculature targeted therapies." Thesis, University of Nottingham, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.495592.

Full text
Abstract:
Tumour growth and metastasis are dependent on the formation and maintenance of a dedicated microvascular network. Angiostatin4.5 (AS4.5) is a naturally occurring anti-angiogenic agent known to inhibit angiogenesis in vitro and tumour growth in vivo.
APA, Harvard, Vancouver, ISO, and other styles
5

Leite, Diana Moreira. "Peptide nanomaterials as targeted endocrine therapies for glioblastoma." Thesis, University of Portsmouth, 2017. https://researchportal.port.ac.uk/portal/en/theses/peptide-nanomaterials-as-targeted-endocrine-therapies-for-glioblastoma(15707f91-4dd4-4220-bf7e-bb008a65b632).html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bolin, Sara. "Mechanisms of Medulloblastoma Dissemination and Novel Targeted Therapies." Doctoral thesis, Uppsala universitet, Neuroonkologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300907.

Full text
Abstract:
Medulloblastomas are the most frequent malignant childhood brain tumors, arising in the posterior fossa of children. The overall 5-year survival is 70%, although children often suffer severe long-term side effects from standard medical care. To improve progression-free survival and quality of life for these children, finding new therapeutic targets in medulloblastoma is imperative. Medulloblastoma is divided in to four molecular subgroups (WNT, SHH, Group 3 and Group 4) based on key developmental pathways essential for the initiation and maintenance of tumor development. The MYC family of prot
APA, Harvard, Vancouver, ISO, and other styles
7

Romanus, Dorothy. "The Value of Targeted Therapies in Lung Cancer." Thesis, Harvard University, 2014. http://nrs.harvard.edu/urn-3:HUL.InstRepos:13070030.

Full text
Abstract:
The goal of this dissertation was to examine the realized value of targeted therapies in routine care and to identify opportunities for improving the return on medical spending for these technologies. Chapter 1 investigated the value of targeted therapies in lung cancer patients who were treated in routine care. This observational, claims-based analysis used propensity score, and instrumental variable methods, combined with a Kaplan Meier Sample Average estimator to calculate lifetime costs and life expectancy. An incremental comparison showed that the realized value of targeted therapies
APA, Harvard, Vancouver, ISO, and other styles
8

Fallaha, Sora. "Targeted Molecular Therapies for HPV-driven Cervical Cancers." Thesis, Griffith University, 2017. http://hdl.handle.net/10072/370595.

Full text
Abstract:
The report by zur Hausen in 1980 linking Human papilloma virus (HPV) infections to major cancers was a key turning point in the HPV-driven cancer discovery era. HPV are doublestranded DNA viruses that belong to the Papillomaviridae family. Most HPV infections resolve spontaneously, or may cause indications (such as warts, anogenital, oro-laryngeal and -pharyngeal papillomas) that are easy to treat. Persistent and untreated infections with certain types of high risk (HR) HPV, particularly types 16 and 18, increase the risk for the development of cancer, such as cervical cancer (CC). In fact, hi
APA, Harvard, Vancouver, ISO, and other styles
9

Stephen, Renu M. "Magnetic Resonance Imaging Biomarkers For Targeted Cancer Therapies." Diss., The University of Arizona, 2008. http://hdl.handle.net/10150/194845.

Full text
Abstract:
In 2007, there will be an estimated 178,480 new cases of breast cancer diagnosed in women in the United States. The elucidation of the vast heterogeneity of individual tumors has led to a paradigm shift from a one-size fits all treatment strategy to more individualized treatment based on the molecular profile of the tumor. Identifying biomarkers that respond to or predict the action of drugs is important in identifying efficacious targets and drugs that will improve clinical outcome. To examine this, we first identified two breast cancer cell lines (ACC-3199 and ACC-3171) from a panel of lo
APA, Harvard, Vancouver, ISO, and other styles
10

Karandish, Fataneh. "Targeted Stimuli-Responsive Carriers for Efficient Delivery of Chemotherapeutic Drugs." Diss., North Dakota State University, 2017. https://hdl.handle.net/10365/26706.

Full text
Abstract:
Chemotherapeutic agents for treating various cancers show considerable side effects and toxicity. Often cancer relapses after initial response to the chemotherapy. Tumor cells are heterogeneous and have the progenitor stem cells which can renew, causing the relapse of the disease. To overcome drug resistance, metastasis, and relapse in cancer, targeted therapy is a promising approach. Targeted delivery of chemotherapeutic agents decrease toxicity and improve efficacy for cancer treatment. We have designed targeted, stimuli-responsive echogenic polymeric vesicles (polymersomes) to not only tran
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Chemotherapeutic and Targeted Therapies"

1

Gioeli, Daniel, ed. Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Dietel, Manfred, ed. Targeted Therapies in Cancer. Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-46091-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Colotta, Francesco, and Alberto Mantovani, eds. Targeted Therapies in Cancer. Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-73898-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Pelaia, Girolamo, Alessandro Vatrella, and Rosario Maselli. Asthma: Targeted Biological Therapies. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-46007-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

(1963-, Marc Lacroix. Targeted Therapies in Cancer. Nova Publishers, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

1950-, Smolen Josef S., and Lipsky Peter E, eds. Targeted therapies in rheumatology. Martin Dunitz, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Salgia, Ravi, ed. Targeted Therapies for Lung Cancer. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17832-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Siemann, Dietmar W., ed. Vascular-Targeted Therapies in Oncology. John Wiley & Sons, Ltd, 2006. http://dx.doi.org/10.1002/0470035439.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Russo, Antonio, Rafael Rosell, and Christian Rolfo, eds. Targeted Therapies for Solid Tumors. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4939-2047-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

W, Siemann Dietmar, ed. Vascular-targeted therapies in oncology. J. Wiley, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Chemotherapeutic and Targeted Therapies"

1

Pavel, Marianne Ellen. "Targeted Therapies." In Neuroendocrine Tumours. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-662-45215-8_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Westphal, Manfred, and Katrin Lamszus. "Targeted Therapies." In Oncology of CNS Tumors. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-02874-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Daste, Amaury. "Targeted Therapies." In Encyclopedia of Gerontology and Population Aging. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-319-69892-2_772-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kessler, Elizabeth, Paul Brittain, S. Lindsey Davis, Stephen Leong, S. Gail Eckhardt, and Christopher H. Lieu. "Targeted Therapies." In The American Cancer Society's Principles of Oncology. John Wiley & Sons, Inc., 2017. http://dx.doi.org/10.1002/9781119468868.ch21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Selvi, Radhakrishna. "Targeted Therapies." In Breast Diseases. Springer India, 2014. http://dx.doi.org/10.1007/978-81-322-2077-0_43.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Marcu, Loredana G., Iuliana Toma-Dasu, Alexandru Dasu, and Claes Mercke. "Targeted Therapies." In Radiotherapy and Clinical Radiobiology of Head and Neck Cancer. CRC Press, 2018. http://dx.doi.org/10.1201/9781351002004-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Daste, Amaury. "Targeted Therapies." In Encyclopedia of Gerontology and Population Aging. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-22009-9_772.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Pavel, Marianne, Suayib Yalcin, and Şahin Laçin. "Targeted Therapies." In Neuroendocrine Tumours. Springer International Publishing, 2024. http://dx.doi.org/10.1007/978-3-031-56968-5_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Cortot, Alexis B., and Pasi A. Jänne. "Resistance to Targeted Therapies As a Result of Mutation(s) in the Target." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Dai, Yun, and Steven Grant. "Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance." In Targeted Therapies. Humana Press, 2011. http://dx.doi.org/10.1007/978-1-60761-478-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Chemotherapeutic and Targeted Therapies"

1

REGAN, KELLY, ZACHARY ABRAMS, MICHAEL SHARPNACK, et al. "DISCOVERY OF MOLECULARLY TARGETED THERAPIES." In Proceedings of the Pacific Symposium. WORLD SCIENTIFIC, 2015. http://dx.doi.org/10.1142/9789814749411_0001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schumann, P. "Ultrasound-Mediated Therapies Using Receptor-Targeted Nanodroplets." In THERAPEUTIC ULTRASOUND: 5th International Symposium on Therapeutic Ultrasound. AIP, 2006. http://dx.doi.org/10.1063/1.2205529.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Grady, Duncan, Marjorie Weiss, and Joanna Pepke-Zaba. "Adherence to pulmonary arterial hypertension targeted therapies." In Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa3786.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Sayles, Leanne C., Amanda Koehne, Kieren Marini, et al. "Abstract 2880: Targeted drug therapies for osteosarcoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2880.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brugge, JS, T. Muranen, J. Zoeller, et al. "DL1-1: Adaptive Resistance to Targeted Therapies." In Abstracts: Thirty-Fourth Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 6‐10, 2011; San Antonio, TX. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/0008-5472.sabcs11-dl1-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Sayles, Leanne C., Amanda Koehne, Kieren Marini, et al. "Abstract 2880: Targeted drug therapies for osteosarcoma." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-2880.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

SUN, Yong, Ying-ju XIU, and Ying XING. "Targeted Therapies for Alzheimer's Disease: An Overview." In 2nd International Conference on Biomedical and Biological Engineering 2017 (BBE 2017). Atlantis Press, 2017. http://dx.doi.org/10.2991/bbe-17.2017.77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Smith, Jessica L., Cecilia Chang, Tim Wang, et al. "Abstract 4864: Targeted melanoma therapies as radiosensitizers." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-4864.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Smith, Jessica L., Cecilia Chang, Tim Wang, et al. "Abstract 4864: Targeted melanoma therapies as radiosensitizers." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-4864.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sayles, Leanne C., Marcus R. Breese, Henry Martell, et al. "Abstract A45: Targeted drug therapies for osteosarcoma." In Abstracts: AACR Special Conference on the Advances in Pediatric Cancer Research; September 17-20, 2019; Montreal, QC, Canada. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.pedca19-a45.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Chemotherapeutic and Targeted Therapies"

1

Huang, Wenbo, Masashi Nagao, Naohiro Yonemoto, and Yuji Nishizaki. Comparative Efficacy Assessment of Different Targeted Therapies and Combinations of Chemotherapeutic Agents for Osteosarcoma: A Bayesian Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2021. http://dx.doi.org/10.37766/inplasy2021.9.0028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Carroll, David. Targeted CNx Nanowire-Drug Complexes for Enhanced Chemotherapeutic Efficacy. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada534933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada485553.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2006. http://dx.doi.org/10.21236/ada454700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rossini, J. G., and Neal Vail. Targeted Therapies For Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada535238.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Malkin, David, and Diana Merino. Molecular Targeted Therapies of Childhood Choroid Plexus Carcinoma. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada592041.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada467829.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Malkin, David. Molecular Targeted Therapies of Childhood Choroid Plexus Carcinoma. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada555024.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Vail, Neal. Targeted Therapies for Myeloma and Metastatic Bone Cancers. Defense Technical Information Center, 2010. http://dx.doi.org/10.21236/ada555410.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Agrafiotis, Apostolos, Mariana Brandão, Thierry Berghmans, Valérie Durieux, and Christiane Jungels. Immunotherapy and targeted therapies efficacy in thymic epithelial tumors: a systematic review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2023. http://dx.doi.org/10.37766/inplasy2023.8.0080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Chemotherapeutic and Targeted Therapies' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography